JC67 OIPE DEC 04 2003 PATENT & TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
DEFOSSA, et al.

Application No.: **10/679,550**

Filed: **October 6, 2003**

Title: **CARBOXYALKOXY-SUBSTITUTED ACYL-CARBOXYPHENYLUREA DERIVATIVES AND THEIR USE AS MEDICAMENTS**

Examiner: Not Yet Known

Art Unit: Not Yet Known

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

December 2, 2003
Date of Deposit

Signature

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.

☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;

☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or

☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is

Therefore, a copy of the reference(s) are not enclosed with this Information Disclosure Statement.

Respectfully submitted,



Barbara E. Kurys, Reg. No. 34,650
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-**2965**
Telefax (908) 231-2626
Aventis Docket No. DEAV2002/0067 US NP

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number	10/679,550
Filing Date	10-06-2003
First Named Inventor	DEFOSSA, et al.
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	DEAV2002/0067 - US - NP

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		6221633		ERTL	04-24-2001	
		6221897		BARINGHAUS	04-24-2001	
		6245744		BARINGHAUS	06-12-2001	
		6342512		KIRSCH	01-29-2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	✓	EP	0 193 249		Duphar Internationál Research	09-03-1986		
	✓	EP	0 462 884		Adir Et Compagnie	12-27-1991		
	✓	DE	10142734		GLOMBIK	03-27-2003		
	✓	DE	DE 694 05 815		Zeneca Ltd.	02-05-1998		
	✓	WO	00/64876		Aventis Pharmaceuticals Prodi	11-02-2000		
	✓	WO	00/64888		Aventis Pharmaceuticals Prodi	11-02-2000		
		WO	01/94300		DEFOSSA	12-13-2001		
		WO	WO 00/40569		Alizyme Therapeutics Limited	07-13-2000		
		WO	WO 00/63208		Novo Nordisk A/S	10-26-2000		
		WO	WO 00/66585		Neurogen Corporation	11-09-2000		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC67 DEC 04 2003 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complet if Known	
Application Number	10/679,550
Filing Date	10-06-2003
First Named Inventor	DEFOSSA, et al.
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	DEAV2002/0067 - US - NP

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO	WO 00/71549		Knoll Aktiengesellschaft	11-30-2000		
		WO	WO 00/78312		Merck & Co., Inc.	12-28-2000		
		WO	WO 01/09111		Eli Lilly And Company	02-08-2001		
		WO	WO 01/83451		Asahi Kasei Kabushiki Kaisha	11-08-2001		
		WO	WO 01/85695		Bristol-Myers Squibb Co.	11-15-2001		
		WO	WO 97/26265		Novo Nordisk A/S	07-24-1997		
		WO	WO 97/41097		Dr. Reddy's Research Founda	11-06-1997		
		WO	WO 98/08871		Novo Nordisk A/S	03-05-1998		
		WO	WO 99/03861		Novo Nordisk A/S	01-28-1999		
		WO	WO 99/15525		Sanofi	04-01-1999		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC67 DEC 04 2003 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Compl te if Known	
Application Number	10/679,550
Filing Date	10-06-2003
First Named Inventor	DEFOSSA, et al.
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	DEAV2002/0067 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		ASAKAWA A. et al., Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism, Anxiety And Gastric Emptying In Mice, Horm Metab Res, (2001), Vol. 33, pp. 554 - 558	
		LEE Daniel W. et al., Leptin Agonists As A Potential Approach To The Treatment Of Obesity, Drugs Of The Future, (2001), Vol. 26, No. 9, pp. 873 - 881	
		OKADA Hiroshi et al., Synthesis And Antitumor Activities Of Prodrugs Of Benzoylphnylureas, Chem. Pharm. Bull., (1994), Vol. 42, No. 1, pp. 57 - 61	
		ROUSSET Monique et al., Growth-Related Glycogen Levels Of Human Intestine Carcinoma Cell Lines Grown In Vitro And In Vivo In Nude Mice, JNCI, (1980), Vol. 65, No. 5, pp. 885 - 889	
		SALVADOR Javier et al., Perspectives In The Therapeutic Use Of Leptin, Expert Opin. Pharmacother., (2001), Vol. 2, No. 10, pp. 1615 - 1622	
		SKWARSKI L. et al., Glycogen Content In The Gastric Mucosa Of Partially Resected Stomach; A Possible Relationship With The Development Of Cancer, Cancer Letters, (1998), Vol. 127, pp. 123 - 128	
		TAKAHASHI Shigeki et al., Estimation Of Glycogen Levels In Human Colorectal Cancer Tissue: Relationship With Cell Cycle And Tumor Outgrowth, J. Gastroenterol, (1999), Vol. 34, pp. 474 - 480	
		TREADWAY Judith L. et al., Glycogen Phosphorylase Inhibitors For Treatment Of Type 2 Diabetes Mellitus, Exp. Opin. Invest. Drugs, (2001), Vol. 10, No. 3, pp. 439 - 454	
		TYLE Praveen, Iontophoretic Devices For Drug Delivery, Pharmaceutical Research, (1986), Vol. 3, No. 6, pp. 318 - 326	
		YANO Kazuyuki et al., Evaluation Of Glycogen Level In Human Lung Carcinoma Tissues By An Infrared Spectroscopic Method , Cancer Letters, (1996), Vol. 110, pp. 29 - 34	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC67 DEC 04 2003 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known	
Application Number	10/679,550
Filing Date	10-06-2003
First Named Inventor	DEFOSSA, et al.
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	DEAV2002/0067 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		ZUNFIT H. J. F. et al., Carob Pulp Preparation For Treatment Of Hypercholesterolemia, Advances In Therapy, (2001), Vol. 18, No. 5, pp. 231 - 236	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.